Targeted radiation zaps prostate cancer cells in new trial
Disease control
Recruiting now
This phase 2 study tests a radioactive antibody, Ac-225 rosopatamab tetraxetan, that seeks out and delivers radiation directly to prostate cancer cells. It is for men with a specific type of advanced prostate cancer that has stopped responding to hormone therapy. The trial aims t…
Phase: PHASE2 • Sponsor: Convergent Therapeutics • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC